JP2022535894A5 - - Google Patents

Info

Publication number
JP2022535894A5
JP2022535894A5 JP2021572445A JP2021572445A JP2022535894A5 JP 2022535894 A5 JP2022535894 A5 JP 2022535894A5 JP 2021572445 A JP2021572445 A JP 2021572445A JP 2021572445 A JP2021572445 A JP 2021572445A JP 2022535894 A5 JP2022535894 A5 JP 2022535894A5
Authority
JP
Japan
Application number
JP2021572445A
Other languages
Japanese (ja)
Other versions
JPWO2020247603A5 (https=
JP2022535894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036084 external-priority patent/WO2020247603A1/en
Publication of JP2022535894A publication Critical patent/JP2022535894A/ja
Publication of JP2022535894A5 publication Critical patent/JP2022535894A5/ja
Publication of JPWO2020247603A5 publication Critical patent/JPWO2020247603A5/ja
Pending legal-status Critical Current

Links

JP2021572445A 2019-06-04 2020-06-04 放出調節製剤およびその使用 Pending JP2022535894A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962856863P 2019-06-04 2019-06-04
US62/856,863 2019-06-04
US202063011584P 2020-04-17 2020-04-17
US63/011,584 2020-04-17
PCT/US2020/036084 WO2020247603A1 (en) 2019-06-04 2020-06-04 Modified release formulations and uses thereof

Publications (3)

Publication Number Publication Date
JP2022535894A JP2022535894A (ja) 2022-08-10
JP2022535894A5 true JP2022535894A5 (https=) 2023-06-13
JPWO2020247603A5 JPWO2020247603A5 (https=) 2023-06-13

Family

ID=73652146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572445A Pending JP2022535894A (ja) 2019-06-04 2020-06-04 放出調節製剤およびその使用

Country Status (4)

Country Link
US (1) US20220323409A1 (https=)
EP (1) EP3980008A4 (https=)
JP (1) JP2022535894A (https=)
WO (1) WO2020247603A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN115487161B (zh) * 2022-11-18 2023-03-03 山东则正医药技术有限公司 一种氨磺必利片的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
WO2010023690A2 (en) * 2008-08-28 2010-03-04 Torrent Pharmaceuticals Ltd. Prolonged release formulation of amisulpride
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
CA3084953A1 (en) * 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2020286441A1 (en) * 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022535893A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)